Table 4: The dynamics of plasma BDNF concentrations and main clinical characteristics in MNCD patients taking escitalopram.

VariablesMNCD-AD group ( = 10)ScVMNCD group ( = 10)
Before treatmentAfter treatmentBefore treatmentAfter treatment

Plasma BDNF concentrations, pg/mL20660.4 ± 12774.626356.0 ± 8309.10.1526652.4 ± 12435.730066.0 ± 10796.40.27
MMSE, score26.5 (26-27)28 (28-29)0.00525 (24–26)27 (26–28)0.005
Delayed recall, TIME test, number of words (0–5)2 (1-2)3.5 (3–5)0.022.5 (2-3)3 (1–4)0.83
Verbal fluency, number of words during 3 min.19.5 (15–25)17.5 (12–24)0.6213 (10–17)17 (10–19)0.20
Clock drawing test, part I, score (0–10)9 (8–10)9 (8–10)0.557 (7-8)7.5 (6–9)0.23
Kinetic apraxia, Luria’s tests, score (0–3)0 (0-1)0 (0-0)0.222 (1–3)2 (1-2)0.48
NPI, total score (0–144)11.5 (9–14)6.5 (6–8)0.007816.5 (9–18)10.5 (7–13)0.011
POMA, score (0–28)25 (24–26)25 (24–26)1.015.5 (13–21)16 (15–21)0.043
BADL, score (0–60)1 (1-1)1 (0-1)0.112 (1-2)2 (1-2)0.98

Data are presented as mean ± standard deviation/median (lower/upper quartile).
: number of patients.
, respectively: according to -test; by Wilcoxon criterion if not otherwise specified.